Vazquez Chris 4

What Happened

• Chris Vazquez, Chief Accounting Officer of Biodesix (BDSX), had 563 restricted stock units (RSUs) convert to 563 shares on Feb 20, 2026 (reported as an exercise/conversion of a derivative). Following the vesting, 211 shares were sold in the open market on Feb 23, 2026 for a weighted average price of $12.78, generating proceeds of $2,696. The sale was an automatic withholding/sale to cover taxes on the RSU vesting.

Key Details

• Transaction dates: RSU conversion/exercise (derivative) on 2026-02-20; sale on 2026-02-23.
• Sale: 211 shares sold at a weighted average price of $12.78; proceeds $2,696. Reported per-share sale prices ranged from $12.58 to $13.16 (weighted avg shown).
• RSU conversion: 563 RSUs converted to 563 shares (reported as derivative exercise/conversion). A disposal entry at $0.00 reflects the conversion/cancellation of the RSUs upon vesting.
• Shares owned after the transactions: not disclosed in the Form 4.
• Footnotes of note:
  • F1: Each RSU equals a contingent right to one share.
  • F2/F3: Shares were sold automatically to cover taxes; sale price is a weighted average; detailed per-trade breakdown is available on request.
  • F4: All share numbers reflect a 1-for-20 reverse split effective Sept 15, 2025.
  • F5: The RSUs vest in four equal annual installments starting Feb 20, 2025, subject to continued service and have no expiration.
• Filing: Form 4 filed Feb 23, 2026 (appears timely relative to the reported dates).

Context

• This was a routine, tax-withholding sale tied to RSU vesting (not an outright discretionary sell by the insider). The derivative activity reflects RSU conversion to common shares (no cash exercise). Such automatic sales to cover withholding are common and do not necessarily indicate the insider's view on the stock.